Porton Pharma Solutions logo

Porton Pharma Solutions

Asia, Heilongjiang, China, Chongqing

Description

Porton Pharma Solutions is a top-tier, China-based external manufacturing partner and strategic supplier of custom drug intermediates

Investor Profile

Porton Pharma Solutions has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B rounds (top funding stages).
  • Majority of deals are located in China.
  • Strong thematic focus on Biotechnology, Genetics, Manufacturing.

Stage Focus

  • Series B (100%)

Country Focus

  • China (100%)

Industry Focus

  • Biotechnology
  • Genetics
  • Manufacturing
  • Pharmaceutical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Porton Pharma Solutions frequently co-invest with?

China Merchants Group
Asia, Hong Kong Island, Hong Kong, Central
Co-Investments: 1
RI
Asia, Guangdong, China, Shenzhen
Co-Investments: 1
Gortune Investment
Asia, Guangdong, China, Guangzhou
Co-Investments: 1
Co-Investments: 1
Fosun Capital
Asia, Shanghai, China, Shanghai
Co-Investments: 1
CS Capital
Asia, Shanghai, China, Shanghai
Co-Investments: 1
China Merchants Securities
Asia, Guangdong, China, Shenzhen
Co-Investments: 1
China Merchants Health
Asia, Hunan, China, Nanshan
Co-Investments: 1
HM Capital
North America, Texas, United States, Dallas
Co-Investments: 1
China Merchants Venture Capital
Asia, Guangdong, China, Shenzhen
Co-Investments: 1

What are some of recent deals done by Porton Pharma Solutions?

Porton Advanced Solutions

Suzhou, Jiangsu, China

Porton Advanced Solutions provide end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.

BiotechnologyGeneticsManufacturingPharmaceuticalTherapeutics
Series BAug 21, 2022
Amount Raised: $80,000,000